• PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action

    2 monthes ago - By San Diego Biotechnology

    As Illumina runs into another regulatory roadblock to expansion, one of its almost-subsidiaries is charging ahead with a new buyout. Pacific Biosciences, often referred to as PacBio, is aiming to swallow rival Omniome in an $800 million stock and cash deal, the companies announced Tuesday morning. PacBio will fork...
    Read more ...